Elliot Stieglitz

47PUBLICATIONS
208CO-AUTHORS
Immunogenetics (incl. genetic immunology)Molecular targetsMedical mycologyHaematological tumoursRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (47)

|Jun 03, 2026
Therapeutic Targeting of IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation in Juvenile Myelomonocytic Leukemia.

|Jun 01, 2026
Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

|Jan 22, 2026
Therapy by omission: observation as a strategy in JMML.

Elliot Stieglitz

|Dec 27, 2025
Concurrent Juvenile Myelomonocytic Leukemia and Gliomas in Patients With Neurofibromatosis Type 1.

Henry Hongo, Sarah K Tasian, Alix E Seif

|Dec 05, 2025
Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia.

Mark Hartmann, Maximilian Schönung, Jovana Rajak

|Oct 27, 2025
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.

Bogdan Popescu, Matthew F Jones, Madison Piao

Pageof 8

Frequent Collaborators

8 joint publications

Mignon L Loh

5 joint publications

Christopher C Dvorak

4 joint publications

Arun Wiita

4 joint publications

Sarah K Tasian